Gemcitabine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gemcitabine" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

16doi.org

2^nd place

14web.archive.org

1^st place

2drugs.com

399^th place

333^rd place

2handle.net

102^nd place

76^th place

2books.google.com

3^rd place

2semanticscholar.org

11^th place

8^th place

1cancercareontario.ca

low place

1cancer.gov

1,684^th place

1,350^th place

1fiercebiotech.com

low place

8,828^th place

1news-medical.net

8,069^th place

7,681^st place

1medicines.org.uk

3,823^rd place

2,387^th place

1fda.gov

447^th place

338^th place

1macmillan.org.uk

low place

1soton.ac.uk

6,219^th place

4,029^th place

1europa.eu

68^th place

117^th place

1fiercepharma.com

low place

8,921^st place

1missouri.edu

3,342^nd place

3,036^th place

1seekingalpha.com

5,344^th place

3,420^th place

1cancernetwork.com

low place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 511. ISBN 9783527607495.
Wang MH, Alexandre D (2015). "Analysis of Cases on Pharmaceutical Patent Infringement in Great China". In Iimura T, Wang MH, Voit TJ, Rader RR (eds.). Law, Politics and Revenue Extraction on Intellectual Property. Cambridge Scholars Publishing. p. 119. ISBN 9781443879262. Archived from the original on 2017-09-11.

cancer.gov

"FDA Approval for Gemcitabine Hydrochloride". National Cancer Institute. 2006-10-05. Archived from the original on 5 April 2017. Retrieved 22 April 2017.

cancercareontario.ca

"Drug Formulary/Drugs/ gemcitabine - Provider Monograph". Cancer Care Ontario. Retrieved 6 December 2020.

cancernetwork.com

Pishvaian MJ, Brody JR (March 2017). "Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159–66, 168. PMID 28299752. Archived from the original on 3 July 2017.

doi.org

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. (December 2020). "Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation". Antiviral Research. 184: 104967. doi:10.1016/j.antiviral.2020.104967. hdl:1765/133780. PMID 33137361.
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). "Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis". Targeted Oncology. 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID 28353074. S2CID 3833614.
Plentz RR, Malek NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427–430. doi:10.1159/000453084. PMC 5290432. PMID 28229078.
Jain A, Kwong LN, Javle M (November 2016). "Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID 27658789. S2CID 25477593.
Siddall E, Khatri M, Radhakrishnan J (July 2017). "Capillary leak syndrome: etiologies, pathophysiology, and management". Kidney International. 92 (1): 37–46. doi:10.1016/j.kint.2016.11.029. PMID 28318633.
Kasi PM (January 2011). "Thrombotic thrombocytopenic purpura and gemcitabine". Case Reports in Oncology. 4 (1): 143–148. doi:10.1159/000326801. PMC 3114619. PMID 21691573.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. (November 2014). "PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564–574. doi:10.1097/fpc.0000000000000086. PMC 4189987. PMID 25162786.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (May 2006). "Cellular pharmacology of gemcitabine". Annals of Oncology. 17 (Suppl 5): v7-12. doi:10.1093/annonc/mdj941. PMID 16807468.
Fatima, M., Iqbal Ahmed, M. M., Batool, F., Riaz, A., Ali, M., Munch-Petersen, B., & Mutahir, Z. (2019). Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 19(4), 342-349. https://doi.org/10.17305/bjbms.2019.4136
Cerqueira NM, Fernandes PA, Ramos MJ (2007). "Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry: A European Journal. 13 (30): 8507–8515. doi:10.1002/chem.200700260. PMID 17636467.
Brown K, Weymouth-Wilson A, Linclau B (April 2015). "A linear synthesis of gemcitabine". Carbohydrate Research. 406: 71–75. doi:10.1016/j.carres.2015.01.001. PMID 25681996.
Brown K, Dixey M, Weymouth-Wilson A, Linclau B (March 2014). "The synthesis of gemcitabine". Carbohydrate Research. 387: 59–73. doi:10.1016/j.carres.2014.01.024. PMID 24636495.
Dyawanapelly S, Kumar A, Chourasia MK (2017). "Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy". Critical Reviews in Therapeutic Drug Carrier Systems. 34 (1): 63–96. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912. PMID 28322141.
Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A (April 2017). "Nanotechnology for delivery of gemcitabine to treat pancreatic cancer". Biomedicine & Pharmacotherapy. 88: 635–643. doi:10.1016/j.biopha.2017.01.071. PMID 28142120.
Dubey RD, Saneja A, Gupta PK, Gupta PN (October 2016). "Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine". European Journal of Pharmaceutical Sciences. 93: 147–162. doi:10.1016/j.ejps.2016.08.021. PMID 27531553.
Krown SE (September 2011). "Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463–468. doi:10.1097/cco.0b013e328349428d. PMC 3465839. PMID 21681092.

drugs.com

"Gemcitabine International Brands". Drugs.com. Archived from the original on 25 May 2014. Retrieved 6 May 2017.
"Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2 February 2017. Retrieved 8 December 2016.

europa.eu

ema.europa.eu

"Gemzar". European Medicines Agency. 24 September 2008. Archived from the original on 11 September 2017.

fda.gov

accessdata.fda.gov

"US formLabel" (PDF). FDA. June 2014. Archived (PDF) from the original on 16 February 2017. Retrieved 6 May 2017. For label updates see FDA index page for NDA 020509 Archived 2017-04-29 at the Wayback Machine

fiercebiotech.com

Myers C (13 March 2009). "Gemcitabine from Actavis launched on patent expiry in EU markets". FierceBiotech. Archived from the original on 11 September 2017.

fiercepharma.com

Myers C (18 August 2009). "Patent for Lilly's cancer drug Gemzar invalidated". FiercePharma. Archived from the original on 11 September 2017.

handle.net

hdl.handle.net

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. (December 2020). "Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation". Antiviral Research. 184: 104967. doi:10.1016/j.antiviral.2020.104967. hdl:1765/133780. PMID 33137361.
World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

macmillan.org.uk

"Gemcitabine". Macmillan Cancer Support. Archived from the original on 25 March 2017. Retrieved 6 May 2017.

medicines.org.uk

"UK label". UK Electronic Medicines Compendium. 5 June 2014. Archived from the original on 10 July 2017. Retrieved 6 May 2017.

missouri.edu

law.missouri.edu

Holman CM (Summer 2011). "Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" (PDF). Missouri Law Review. 76 (3): 645–693. Archived from the original (PDF) on 2017-09-11. Retrieved 2017-05-06.

news-medical.net

"Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection". Hospira via News-Medical.Net. 16 November 2010. Archived from the original on 2 October 2015.

nih.gov

pubmed.ncbi.nlm.nih.gov

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. (December 2020). "Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation". Antiviral Research. 184: 104967. doi:10.1016/j.antiviral.2020.104967. hdl:1765/133780. PMID 33137361.
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). "Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis". Targeted Oncology. 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID 28353074. S2CID 3833614.
Plentz RR, Malek NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427–430. doi:10.1159/000453084. PMC 5290432. PMID 28229078.
Jain A, Kwong LN, Javle M (November 2016). "Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID 27658789. S2CID 25477593.
Siddall E, Khatri M, Radhakrishnan J (July 2017). "Capillary leak syndrome: etiologies, pathophysiology, and management". Kidney International. 92 (1): 37–46. doi:10.1016/j.kint.2016.11.029. PMID 28318633.
Kasi PM (January 2011). "Thrombotic thrombocytopenic purpura and gemcitabine". Case Reports in Oncology. 4 (1): 143–148. doi:10.1159/000326801. PMC 3114619. PMID 21691573.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. (November 2014). "PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564–574. doi:10.1097/fpc.0000000000000086. PMC 4189987. PMID 25162786.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (May 2006). "Cellular pharmacology of gemcitabine". Annals of Oncology. 17 (Suppl 5): v7-12. doi:10.1093/annonc/mdj941. PMID 16807468.
Cerqueira NM, Fernandes PA, Ramos MJ (2007). "Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry: A European Journal. 13 (30): 8507–8515. doi:10.1002/chem.200700260. PMID 17636467.
Brown K, Weymouth-Wilson A, Linclau B (April 2015). "A linear synthesis of gemcitabine". Carbohydrate Research. 406: 71–75. doi:10.1016/j.carres.2015.01.001. PMID 25681996.
Brown K, Dixey M, Weymouth-Wilson A, Linclau B (March 2014). "The synthesis of gemcitabine". Carbohydrate Research. 387: 59–73. doi:10.1016/j.carres.2014.01.024. PMID 24636495.
Dyawanapelly S, Kumar A, Chourasia MK (2017). "Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy". Critical Reviews in Therapeutic Drug Carrier Systems. 34 (1): 63–96. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912. PMID 28322141.
Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A (April 2017). "Nanotechnology for delivery of gemcitabine to treat pancreatic cancer". Biomedicine & Pharmacotherapy. 88: 635–643. doi:10.1016/j.biopha.2017.01.071. PMID 28142120.
Dubey RD, Saneja A, Gupta PK, Gupta PN (October 2016). "Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine". European Journal of Pharmaceutical Sciences. 93: 147–162. doi:10.1016/j.ejps.2016.08.021. PMID 27531553.
Pishvaian MJ, Brody JR (March 2017). "Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159–66, 168. PMID 28299752. Archived from the original on 3 July 2017.
Krown SE (September 2011). "Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463–468. doi:10.1097/cco.0b013e328349428d. PMC 3465839. PMID 21681092.

ncbi.nlm.nih.gov

Plentz RR, Malek NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427–430. doi:10.1159/000453084. PMC 5290432. PMID 28229078.
Kasi PM (January 2011). "Thrombotic thrombocytopenic purpura and gemcitabine". Case Reports in Oncology. 4 (1): 143–148. doi:10.1159/000326801. PMC 3114619. PMID 21691573.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. (November 2014). "PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564–574. doi:10.1097/fpc.0000000000000086. PMC 4189987. PMID 25162786.
Krown SE (September 2011). "Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463–468. doi:10.1097/cco.0b013e328349428d. PMC 3465839. PMID 21681092.

seekingalpha.com

Ravicher DB (28 July 2010). "On the Generic Gemzar Patent Fight". Seeking Alpha. Archived from the original on 9 December 2012.

semanticscholar.org

api.semanticscholar.org

Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA (June 2017). "Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis". Targeted Oncology. 12 (3): 309–321. doi:10.1007/s11523-017-0486-5. PMID 28353074. S2CID 3833614.
Jain A, Kwong LN, Javle M (November 2016). "Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. doi:10.1007/s11864-016-0432-2. PMID 27658789. S2CID 25477593.

soton.ac.uk

eprints.soton.ac.uk

Brown K, Dixey M, Weymouth-Wilson A, Linclau B (March 2014). "The synthesis of gemcitabine". Carbohydrate Research. 387: 59–73. doi:10.1016/j.carres.2014.01.024. PMID 24636495.

web.archive.org

"Gemcitabine International Brands". Drugs.com. Archived from the original on 25 May 2014. Retrieved 6 May 2017.
"Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2 February 2017. Retrieved 8 December 2016.
"FDA Approval for Gemcitabine Hydrochloride". National Cancer Institute. 2006-10-05. Archived from the original on 5 April 2017. Retrieved 22 April 2017.
Myers C (13 March 2009). "Gemcitabine from Actavis launched on patent expiry in EU markets". FierceBiotech. Archived from the original on 11 September 2017.
"Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection". Hospira via News-Medical.Net. 16 November 2010. Archived from the original on 2 October 2015.
"UK label". UK Electronic Medicines Compendium. 5 June 2014. Archived from the original on 10 July 2017. Retrieved 6 May 2017.
"US formLabel" (PDF). FDA. June 2014. Archived (PDF) from the original on 16 February 2017. Retrieved 6 May 2017. For label updates see FDA index page for NDA 020509 Archived 2017-04-29 at the Wayback Machine
"Gemcitabine". Macmillan Cancer Support. Archived from the original on 25 March 2017. Retrieved 6 May 2017.
"Gemzar". European Medicines Agency. 24 September 2008. Archived from the original on 11 September 2017.
Myers C (18 August 2009). "Patent for Lilly's cancer drug Gemzar invalidated". FiercePharma. Archived from the original on 11 September 2017.
Holman CM (Summer 2011). "Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" (PDF). Missouri Law Review. 76 (3): 645–693. Archived from the original (PDF) on 2017-09-11. Retrieved 2017-05-06.
Ravicher DB (28 July 2010). "On the Generic Gemzar Patent Fight". Seeking Alpha. Archived from the original on 9 December 2012.
Wang MH, Alexandre D (2015). "Analysis of Cases on Pharmaceutical Patent Infringement in Great China". In Iimura T, Wang MH, Voit TJ, Rader RR (eds.). Law, Politics and Revenue Extraction on Intellectual Property. Cambridge Scholars Publishing. p. 119. ISBN 9781443879262. Archived from the original on 2017-09-11.
Pishvaian MJ, Brody JR (March 2017). "Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159–66, 168. PMID 28299752. Archived from the original on 3 July 2017.